As cases of Covid-19 continue to climb in the U.S., some analysts are arguing that vaccines aren’t enough to fight the virus, and that a substantial commercial opportunity remains for companies that develop effective therapeutics.
“Despite their relative lack of efficacy and lack of convenience, the small number of approved and authorized products still managed to achieve collective 1QCY21 sales of more than $3bn,” the analysts wrote. “An effective and convenient treatment could potentially achieve peak annual sales in excess of $10bn.”